Endocrinology (all articles)
RCT | No significant kidney outcome differences observed across glucose-lowering medications in T2D patients
15 Jun, 2023 | 15:02h | UTCComparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
See also: Visual Abstract
Commentaries:
No differences found in effects of secondary diabetes drugs on kidney outcomes – ACP Diabetes
Do glucose-lowering medications have different effects on kidney outcomes? – News Medical
SR | Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes
15 Jun, 2023 | 14:57h | UTC
Cohort Study | Weight change and risk of obesity-related complications
15 Jun, 2023 | 14:53h | UTC
Commentary from the author on Twitter
Our paper showing association of weight loss on risk of developing 13 obesity-related complications
Weight loss benefit dependent on weight loss magnitude & initial BMI-weight gain associated with a similar risk ⬆️
4 patterns of association identifiedhttps://t.co/7iQCCsIJ3x pic.twitter.com/xVVLruS6Jg
— Prof Kamlesh Khunti (@kamleshkhunti) June 8, 2023
Consensus Statement | Use of liothyronine (T3) in hypothyroidism
13 Jun, 2023 | 13:46h | UTC
M-A | Elevated HbA1c in gestational diabetes mellitus tied to 1.7-fold rise in large for gestational age incidence
13 Jun, 2023 | 13:39h | UTC
M-A | Clinical outcomes associated with drugs for obesity and overweight
12 Jun, 2023 | 13:24h | UTC
Guideline Series | Prevention and management of diabetes-related foot disease
7 Jun, 2023 | 13:41h | UTCDefinitions and criteria for diabetes-related foot disease (IWGDF 2023 update)
Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update)
Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update)
RCT | Tirzepatide outperforms insulin glargine in HbA1c reduction and weight loss in type 2 diabetes
6 Jun, 2023 | 14:39h | UTC
Commentary on Twitter
The SURPASS-AP-Combo trial shows that addition of #tirzepatide as 2L or 3L therapy is non-inferior & superior to insulin glargine for glycemic outcomes at 40 weeks in an Asia-Pacific (mostly Chinese) population w/ type 2 #diabetes. https://t.co/RDh2WSJ1wZ pic.twitter.com/nm6pPpVdxH
— Nature Medicine (@NatureMedicine) June 2, 2023
Podcast | Insulin, type 2 diabetes, and hypoglycemia
6 Jun, 2023 | 14:25h | UTC#397: Insulin, Type 2 Diabetes, Fanny Packs, and Hypoglycemia with Dr. Jeff Colburn – The Curbsiders
Adrenal failure: an evidence-based diagnostic approach
6 Jun, 2023 | 14:16h | UTCAdrenal Failure: An Evidence-Based Diagnostic Approach – Diagnostics
M-A | Significant non-alcoholic fatty liver disease prevalence in South Asia, many non-obese affected
6 Jun, 2023 | 14:00h | UTC
Review | Subclinical hypothyroidism: let the evidence be your guide
2 Jun, 2023 | 12:08h | UTCSubclinical hypothyroidism: Let the evidence be your guide – Journal of Family Practice
Phase 2b RCT | Danuglipron, an oral GLP-1R agonist, reduces body weight and improves glycemic control in type 2 diabetes
1 Jun, 2023 | 12:17h | UTC
SR | Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly
1 Jun, 2023 | 11:52h | UTC
M-A | Plant-based diets reduce key atherogenic lipoproteins
30 May, 2023 | 11:48h | UTCEditorial: Plant-based dietary patterns and atherogenic lipoproteins – European Heart Journal
Review | Child and adolescent obesity
30 May, 2023 | 11:45h | UTCChild and adolescent obesity – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Commentary on Twitter
A Primer in @DiseasePrimers discusses the epidemiology, mechanisms, diagnosis, prevention and management of obesity in children and adolescents, highlighting patient quality of life and areas for further research. https://t.co/Zpcb4RbH2J pic.twitter.com/uneXxVyTDg
— Nature Portfolio (@NaturePortfolio) May 28, 2023
Review | Managing menopausal symptoms, fertility, and bone health in breast cancer women on endocrine therapy
30 May, 2023 | 11:40h | UTC
Clinical Trial Update | Mesenteric defects closure in bariatric surgery cuts reoperation rate due to bowel obstruction
29 May, 2023 | 10:49h | UTCLong-term Safety and Efficacy of Closure of Mesenteric Defects in Laparoscopic Gastric Bypass Surgery: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract
A pragmatic approach to the management of menopause
25 May, 2023 | 11:30h | UTCA pragmatic approach to the management of menopause – Canadian Medical Association Journal
News Release: Managing menopause: Hormone therapy is back – Canadian Medical Association Journal
Review | Exercise training and revascularization in the management of symptomatic peripheral artery disease
25 May, 2023 | 11:23h | UTC
Commentary on Twitter
Exercise Therapy and Revascularization in the Management of Symptomatic Peripheral Artery Diseasehttps://t.co/Nywh4YxIs3 pic.twitter.com/K8z7E5eK9v
— Physio Meets Science (@PhysioMeScience) May 7, 2023
Graves’ disease in children: an update
25 May, 2023 | 11:18h | UTCGraves’ Disease in Children: An Update – Clinical Medicine Insights: Endocrinology and Diabetes
Guidelines on the diagnosis and treatment of foot infection in persons with diabetes
24 May, 2023 | 13:30h | UTC
RCT | Spironolactone enhances acne outcomes and offers a viable alternative to oral antibiotics
24 May, 2023 | 13:27h | UTCSummary: The SAFA (Spironolactone for Adult Female Acne) trial was a multicenter, phase 3, double-blind, randomized controlled trial in England and Wales and evaluated the efficacy of spironolactone for treating adult women with acne vulgaris. A total of 410 women, aged ≥18 years and suffering from facial acne for a minimum of six months, were randomly assigned to receive either 50 mg/day of spironolactone or a placebo, increasing to 100 mg/day until week 24.
The primary outcome was measured by the Acne-Specific Quality of Life (Acne-QoL) symptom subscale score at week 12 and 24. The trial demonstrated that spironolactone improved Acne-QoL scores more effectively than the placebo, particularly at week 24. Additionally, more participants in the spironolactone group reported acne improvement, and treatment success was significantly higher in this group at week 12. Mild side effects, notably headaches, were more common in the spironolactone group.
The findings from the SAFA trial highlight spironolactone’s effectiveness, safety, and tolerability in treating adult women with acne vulgaris, suggesting it is a viable alternative to long-term antibiotic treatments. Future research is proposed on higher initial dosages of spironolactone, and its effects on different subgroups like patients with different ages, body mass index, and ethnicity.
Editorial: What do we know about prescribing spironolactone for acne? – The BMJ
News Release: Non-antibiotic treatment for women with persistent acne shown to be effective – University of Southhampton
Review | Glycemic management in people with diabetes on peritoneal dialysis
24 May, 2023 | 13:04h | UTC
Commentary on Twitter (thread – click for more)
1/Hey #Nephtwitter #Medtwitter
Today, we are discussing
Clinical considerations while managing diabetes on Peritoneal dialysis (PD)#Tweetorial alert ?@KIReports
Full text link: https://t.co/sOEIa6AuNh pic.twitter.com/kVn4XDYylU— KIReports (@KIReports) May 20, 2023
Opinion Video | Questioning the reliability of nutrition science
23 May, 2023 | 13:02h | UTC